News

Novo slips in obesity-med fight
Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...
Health on MSN15h
Zepbound or Wegovy? Head-to-Head Trial Says One Is Better for Weight Loss
Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...
Hims & Hers: Not The Dip I Want To Buy (Rating Downgrade)
Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...
Americans scramble as weight-loss drug discounts fall short, copies face crackdown
(Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs ...
Zacks Investment Research on MSN19h
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
The obesity market has garnered much interest lately, propelled by the success of GLP-1 therapies Wegovy and Zepbound, marketed by pharma giants Novo Nordisk NVO and Eli Lilly LLY, respectively. This ...
US patients struggle as weight-loss drug discounts fall short
About a dozen activists from the Extinction Rebellion climate group briefly occupied the entrance lobby of French bank BNP ...